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nteric fever
a  b  s  t  r  a  c  t
Salmonella  enterica  serovars  Typhi  and  Paratyphi  (S. Paratyphi)  A  and  B cause  enteric  fever  in  humans.
Of  the  paratyphoid  group,  S. Paratyphi  A is the  most  common  serovar.  In  2000, there  were  an  estimated
5.4  million  cases  of S.  Paratyphi  A worldwide.  More  recently  paratyphoid  fever  has  accounted  for  an
increasing  fraction  of  all cases  of enteric  fever.  Although  vaccines  for typhoid  fever have been  developed
and  in  use  for  decades,  vaccines  for paratyphoid  fever  have  not  yet  been  licensed.  Several  S. Paratyphi  A
vaccines,  however,  are  in development  and  based  on  either  whole  cell  live-attenuated  strains  or  repeating
units of  the  lipopolysaccharide  O-antigen  (O:2)  conjugated  to different  protein  carriers.  An O-speciﬁc
polysaccharide  (O:2)  of  S. Paratyphi  A conjugated  to tetanus  toxoid  (O:2-TT),  for  example,  has  beeneveloping countries
accine policy
almonella paratyphi
almonella paratyphi A
determined  to be  safe  and  immunogenic  after one  dose  in  Phase  I and  Phase  II trials.  Two  other  conjugated
vaccine  candidates  linked  to  diphtheria  toxin  and  a live-attenuated  oral  vaccine  candidate  are  currently  in
preclinical  development.  As promising  vaccine  candidates  are  advanced  along  the  development  pipeline,
an  adequate  supply  of vaccines  will  need  to  be ensured  to meet growing  demand,  particularly  in the  most
affected  countries.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CCSalmonella bacteria, of the Enterobacteriaceae family, comprise
 group of Gram-negative, non-spore-forming, facultative anaer-
bic bacilli [1]. Collectively, these bacteria are responsible for
 broad-spectrum of gastrointestinal and systemic illnesses that
nclude but are not limited to enteric fever, food-borne diarrheal
llness and invasive nontyphoidal Salmonella disease. Salmonella
nterica serovar Typhi (S. Typhi) and Salmonella enterica serovar
aratyphi (S. Paratyphi) A and B cause enteric fever, a febrile illness
xclusively in humans. Of the paratyphoid group, S. Paratyphi A is
he most common serovar. The remaining Salmonella bacteria are
ostly zoonotic nontyphoidal serotypes that tend to infect a variety
f hosts [2]. In 2000, there were an estimated 5.4 million cases of S.
aratyphi A worldwide [3], with highest burdens on the Indian sub-
ontinent and South East Asia. Unlike NTS and S. Typhi, there does
ot seem to be such high burden of paratyphoid in sub-Saharan
frica.
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Studies from South Asia have reported an increased number
of paratyphoid fever cases, but the same has not been true in
other regions. For example, there is a high prevalence of S. Typhi
in urban areas of Kenya, Malawi, Tanzania and the Democratic
Republic of Congo but virtually no reports of S. Paratyphi [4,5].
Low prevalence, however, does not translate into low risk. Severe
complications from S. Paratyphi infection mirror those of S. Typhi,
including hypotensive shock, small bowel perforation, bradycardia,
meningitis, osteomyelitis and multi-organ abscesses [6]. Chronic
carriage and long-term bacterial shedding, well characterized for
S. Typhi, has also been described for S. Paratyphi A [7]. Because
patients with S. Paratyphi A generally present with non-speciﬁc
febrile illness, diagnosis is dependent on laboratory conﬁrmation.
However, there is a relative lack of reliable diagnostics for enteric
fever, so most cases are treated without isolating or serotyping the
infecting organism. The gold standard for diagnosis remains bone-
marrow culture (80–95% sensitive). However, this is rarely used
and is instead substituted with blood culture in areas where it is
available. Stool culture can also be utilized as a means for case
identiﬁcation but may  require a logistically challenging collection
of multiple samples to increase sensitivity.
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The lack of a clinically relevant animal model has made it difﬁ-
ult to develop improved diagnostics. However, a number of new
iagnostic technologies are being developed de novo or adapted
rom other ﬁelds. For example, researchers at the International
entre for Diarrheal Disease Research, Bangladesh recently devel-
ped the TPTest which detects Salmonella-speciﬁc IgA responses
n lymphocyte culture supernatant [8]. Results of the TPTest can
e used to distinguish enteric fever infection; it cannot, however,
ifferentiate between S. Typhi and S. Paratyphi A. Furthermore,
he time to identiﬁcation is not signiﬁcantly faster than blood cul-
ure. Molecular methodologies such as quantitative real-time PCR,
NA ﬁngerprinting, pulse-ﬁeld electrophoresis and, more recently,
hole-genome sequencing are also being used to differentiate
nd quantify bacterial strains in clinical samples. The sensitivity
nd speciﬁcity of these diagnostics are inﬂuenced by multiple fac-
ors, including antimicrobial use, bacterial burden in the peripheral
lood, the timing of blood collection and the volume of blood col-
ected, particularly for children under the age of ﬁve years. Despite
heir potential, these leading-edge technologies may  not be avail-
ble in most resource-constrained laboratories for some time.
The strategies and challenges of preventing and treating paraty-
hoid are similar to those for typhoid. The treatment of S. Paratyphi
as been complicated in recent years by the emergence of antimi-
robial resistance, speciﬁcally to ﬂuoroquinolones and naladixic
cid [9,10]. There is evidence that S. Paratyphi A has a greater
endency toward resistance than S. Typhi. Furthermore, when treat-
ent is given, it can often be delayed due to the non-speciﬁc
ature of clinical symptoms and the lack of a reliable test for either
nfection or drug resistance. Because paratyphoid is spread by the
ecal-oral route, provision of safe drinking water and uncontam-
nated food coupled with implementation of standard hygienic
ractices can signiﬁcantly reduce transmission in endemic sett-
ngs. As S. Paratyphi A is primarily transmitted outside of the
ome [11], case identiﬁcation and treatment of travelers can be
ffective in preventing outbreaks [12]. While the most effective
eans of controlling S. Paratyphi is through the availability of clean
ater supplies and working sanitation services, these infrastruc-
ural changes tend to occur slowly. Given the complexities and
imitations of other interventions, the development of a safe and
ffective vaccine remains a priority for controlling the spread of
aratyphoid disease.
. Biological feasibility and general approaches for
aratyphoid vaccine development for low- and
iddle-income markets
Vaccines for S. Paratyphi are currently not available. However,
icrobiological similarities between serovar S. Typhi and S. Paraty-
hi A and the fact that there are licensed, available vaccines for
. Typhi support the biological feasibility for S. Paratyphi vaccine
evelopment. A killed, whole-cell parenteral TAB (Typhi/Paratyphi
/Paratyphi B) vaccine was used for several decades and consisted
f killed strains of 1000 million S. Typhi, 750 million S. Paratyphi
, and 750 million S. Paratyphi B cells that provided some level of
rotective immunity against infection. Although this vaccine is no
onger administered on account of its relatively severe side effects,
he development of the vaccine attests to the possibility of vaccine-
nduced protection against S. Paratyphi [13]. S. Paratyphi A vaccines
urrently in development are primarily based on whole-cell live-
ttenuated strains and repeating units of the lipopolysaccharide
-antigen, (O:2) conjugated to a range of protein carriers. Recently,
accination with the oral, live-attenuated S. Typhi vaccine, Ty21a
train, has been shown to elicit a humoral immune response with
n vitro cross-reactivity against S. Paratyphi A and B [13]. Addi-
ional efforts are underway to develop subunit vaccines based on4 (2016) 2900–2902 2901
the lipopolysaccharide antigen that has been previously described
as a virulence factor and a target of host immunity [14]. Regardless
of the type of vaccine developed, the co-endemicity of paratyphoid
A with typhoid fever in areas such as South and Southeast Asia, will
likely require a bivalent vaccine with a focus on infants and young
children.
2. Technical and regulatory assessment
In 2013, the World Health Organization published a guidance
document on the regulation and prequaliﬁcation of typhoid con-
jugate vaccines [15]. Although no such pathway has yet been
developed for paratyphoid vaccines, the typhoid vaccine frame-
work can serve as a surrogate until one is established. There is
currently no immune correlate of protection identiﬁed for S. Paraty-
phi A in humans as exists for anti-Vi and protection from S. Typhi
infection. There are, however, in vitro assays that quantify the
positive correlation between serum antibody levels and in vitro
bactericidal activity (SBA) induced by either natural infection or
immunization. Still, there is no well-established animal model for
S. Paratyphi A infection to evaluate pre-clinical efﬁcacy. To address
this deﬁciency in vaccine development, an experimental human
challenge model using S. Paratyphi A is being developed [16] to
evaluate clinical outcomes and immune response following natural
infection and vaccination.
3. Status of vaccine R&D activities
Several research groups and vaccine manufacturers are in the
process of developing monovalent S. Paratyphi A and bivalent S.
Paratyphi A/S. Typhi glycoconjugate vaccines (Table 1). The US
National Institutes of Health (NIH) has developed an O-speciﬁc
polysaccharide (O:2) conjugated to tetanus toxoid (O:2-TT) that
was found, in Phase 1 and 2 trials, to be both safe and immuno-
genic after one dose, although a booster antibody response was  not
evident after a second dose [17]. The NIH transferred the technol-
ogy to the Chengdu and Lanzhou Institutes of Biological Products in
China, the latter of which is currently conducting additional Phase
2 trials. The GSK Vaccines Institute for Global Health, with funds
from the Wellcome Trust, developed an S. Paratyphi A conjugate
using O:2 conjugated to CRM197, a nontoxic mutant of diphtheria
toxin (O:2-CRM197), intended to be combined in a bivalent formu-
lation with Vi-CRM197. This vaccine component has been shown
to be immunogenic with strong SBA against S. Paratyphi A when
delivered alone or in combination with Vi-CRM197. SBVGH trans-
ferred this technology to Biological E, Ltd. in India, which intends
to commercialize a bivalent vaccine—comprising Vi-CRM197 and
O:2-CRM197—that has activity against S. Typhi and S. Paratyphi
A[18]. The International Vaccine Institute has also conjugated the
O:2 of S. Paratyphi A to diphtheria toxoid (O:2-DT), though with an
adipic acid dihydrazide linker [19]. Clinical testing of this product
has not yet commenced. Finally, the Center for Vaccine Develop-
ment at the University of Maryland Baltimore (UMB) has developed
a live-attenuated, oral vaccine candidate for S. Paratyphi A (CVD
1902). The vaccine has two  independently attenuating mutations
in guaBA and clpX and has been shown to be safe and immunogenic
in preclinical studies [20]. A single dose of CVD 1902 was  also well
tolerated and immunogenic in Phase I trials. UMB  has licensed the
product to Bharat Biotech Ltd, Hyderabad, India, which will direct
future vaccine production and clinical research with guidance from
UMB. CVD 1902 is intended to ultimately become a part of a bivalent
vaccine, along with the live attenuated CVD 909 vaccine candidate
that targets S. Typhi.
2902 L.B. Martin et al. / Vaccine 34 (2016) 2900–2902
Table 1
Development status of current Salmonella Paratyphoid A vaccine candidates (POC = proof-of-concept trial).
Candidate name/identiﬁer Preclinical Phase I Phase II POC Phase III
O:2,12-TT + Vi-TT [NIH, Lanzhou] X
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[O:2,12-CRM197 + Vi-CRM197 [Biological E and SVGH] X
CVD 1902 + CVD 909 [UMB, Bharat Biotech] 
O:2,12-DT + Vi-DT [International Vaccine Institute] X
. Likelihood for ﬁnancing
Though paratyphoid fever has garnered some attention from
lobal health funding agencies, commitment for vaccine develop-
ent, licensure and deployment requires sustained efforts. The
trategic Advisory Group of Experts on Immunization, in 2011,
ighlighted the need for developing a combined typhoid and
aratyphoid vaccine [21]. Despite these efforts, no concrete steps
y the GAVI Alliance have been taken for designating a priority
or vaccines against paratyphoid A, as was done for typhoid con-
ugate vaccines in 2008. The implementation of a Phase III clinical
rial to establish efﬁcacy the most promising S. Paratyphi A vac-
ine candidate will require funding from a variety of sources. With
he increasing burden of disease from S. Paratyphi A, and growing
ttention to the identity of Salmonella enterica serovars responsible
or invasive Salmonella disease, control through vaccines appears to
ecome a signiﬁcant global health priority. Whether vaccines for
aratyphoid will be cost-effective as compared to other preven-
ive interventions, will require rigorous studies once paratyphoid
accines have shown to be efﬁcacious.
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